Reuters logo
BRIEF-Ultragenyx reports positive mid-stage data to treat long-chain fatty acid oxidation disorder
November 30, 2016 / 1:50 PM / a year ago

BRIEF-Ultragenyx reports positive mid-stage data to treat long-chain fatty acid oxidation disorder

Nov 30 (Reuters) - Ultragenyx Pharmaceutical Inc -

* Ultragenyx announces positive data from phase 2 study of UX007 in long-chain fatty acid oxidation disorder patients

* Ultragenyx announces positive data from phase 2 study of UX007 in long-chain fatty acid oxidation disorder patients

* Says frequency and duration of major medical events were reduced significantly during treatment with UX007

* Says patients demonstrated improved exercise tolerance and quality of life during study

* Continue to further develop phase 3 study design and endpoints before meeting with regulators and initiating study in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below